Home  /  Resource Library  /  Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab

Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab

Study investigated long term immune system effects from treatment with venetoclax and rituximab.

Related Articles

Editorial Guidelines

To ensure the integrity of all content produced by the Lymphoma Coalition (LC), a rigorous process has been put

Learn More

Transparency With Corporations...

This document outlines LC’s policy on commercial funding and provides a set of principles that will be used to guide LC’s decisions. It does not...

Learn More